|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer显示文摘 | Yoon-Koo Kang Kei Muro Min-Hee Ryu Hirofumi Yasui Tomohiro Nishina Baek-Yeol Ryoo Yukimasa Kamiya Shiro Akinaga Narikazu Boku | 2014 | Investigational New Drugs2014，，2： | 5 |
| 2 | Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w显示文摘Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese patients.Methods: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than 1.3.Conclusion: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence for XELIRI with or without bevacizumab as a second?line treatment option of mCRC. | Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim | 2016 | Chinese Journal of Cancer2016，35，12： | 3 |
| 3 | Aminoguanidine attenuates endo toxin ind uced acute lung injury in rabbits显示文摘 | Mikawa K Nishina K Tamada M | | 0，，： | 2 |
| 4 | Phase II trial of nanoparticle albumin‐bound paclitaxel as second‐line chemotherapy for unresectable or recurrent gastric cancer显示文摘 | Yasutsuna Sasaki Tomohiro Nishina Hirofumi Yasui Masahiro Goto Kei Muro Akihito Tsuji Wasaburo Koizumi Yasushi Toh Takuo Hara Yoshinori Miyata | 2014 | Cancer Sci2014，，7： | 2 |
| 5 | Propofol inhibits human neutrophil functions 显示文摘 | Mikawa K Akametsu K Nishina K | 1998 | Anesth Analg1998，87，3： | 1 |
| 6 | Effects of phos- phodiesterase-Ⅲ inhibitors on sevoflurane-induced impairment of rat diaphragmatic function显示文摘 | UESUGI T MIKAWA K NISHINA K | 2005 | Acta Anaesthesiol Scand2005，49，6： | 1 |
| 7 | Enhanced production of L(+)-lactic acid from corn starch in a culture of Rhizopus oryzae using an air-lift bioreactor显示文摘 | YIN P NISHINA N KOSAKAI Y | 1997 | Journal of Fermentation and Bioengineering1997，84，3： | 1 |
| 8 | Attention of cardiovascular responses to tracheal extubatiob:verapamil versus diltiaxem显示文摘 | Mikawa K Nishina K Mackawa N | 1996 | Anesth Analg1996，82，6： | 1 |
| 9 | Intratracheal application of recombinant surfactant protein-C surfactant to rabbits attenuates acute lung injury induced by intratracheal acidified infant formula 显示文摘 | Mikawa K Nishina K Takao Y | 2004 | Anesth Analg2004，98，5： | 1 |
| 10 | A 10-year retrospective cohort study on the risk factors for peritoneal dialysis-related peritonitis:a single-center study at Tokai University Hospital显示文摘 | Nishina M Yanagi H Kakuta T | 2013 | Clin & Experi Nephrol2013，，： | 1 |
| 11 | Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin显示文摘 | Kiyonari Y Nishina K Mikawa K | | 0，，02： | 1 |
| 12 | Identification of a novel Sry-related gene and its germ cell-specific expression显示文摘 | Osaki El Nishina Y Inazawa J | 1999 | Nucleic Acids Res1999，27，12： | 1 |
| 13 | Tribological properties of monolayer graphene oxide sheets as water-based lubricant additives显示文摘 | K1NOSHITA H NISHINA Y ALIAS A A | 2014 | Carbon2014，66，： | 1 |
| 14 | Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers 显示文摘 | Nasu J Nishina T Hirasaki S | 2006 | J Clin Gastroenterol2006，40，5： | 1 |
| 15 | The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5-deoxy-5-fluor-ouridine显示文摘 | Nishina T Hyldl I Miyaike J | 2004 | Eur J Cancer2004，40，10： | 1 |
| 16 | ONO-5046,an elastase inhibitor,attenuates endotoxin-induced acute lung injury in rab-bits显示文摘 | Nishina K Mikawa K Takao Y | 1997 | Anesth Analg1997，84，5： | 1 |
| 17 | Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair 显示文摘 | Tsuneyoshi H Nishina T Nomoto T | 2004 | Circulation2004，110，11： | 1 |
| 18 | Alstr?m syndrome: further evidence for linkage to human chromosome 2p13显示文摘 | G.B. Collin J.D. Marshall C.F. Boerkoel A.V. Levin R. Weksberg J. Greenberg J.L. Michaud J.K. Naggert P.M. Nishina | 1999 | Human Genetics1999，，5： | 1 |
| 19 | Pax6 missense mutation in isolated foveal hypoplasia 显示文摘 | Azuma N Nishina S Yanagisawa H | 1996 | Nat Genet1996，13，： | 1 |
| 20 | Dose-response of flurbiprofen on postoperative pain and emesis after paediatric strabismus surgery 显示文摘 | Mikawa K Nishina K Maekawa N | 1997 | Can J Anaesth1997，44，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员